|
1
|
Hayes JD, Dinkova-Kostova AT and Tew KD:
Oxidative Stress in Cancer. Cancer Cell. 38:167–197. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kaminski MM, Sauer SW, Kaminski M, Opp S,
Ruppert T, Grigaravicius P, Grudnik P, Grone HJ, Krammer PH and
Gülow K: T cell activation is driven by an ADP-dependent
glucokinase linking enhanced glycolysis with mitochondrial reactive
oxygen species generation. Cell Rep. 2:1300–1315. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ishikawa K, Takenaga K, Akimoto M,
Koshikawa N, Yamaguchi A, Imanishi H, Nakada K, Honma Y and Hayashi
J: ROS-Generating Mitochondrial DNA mutations can regulate tumor
cell metastasis. Science. 320:661–664. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zong X, Cao X, Wang H, Xiao X, Wang Y and
Lu Z: Cathelicidin-WA Facilitated intestinal fatty acid absorption
through enhancing PPAR-ү dependent barrier function. Front Immunol.
10:16742019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Angela M, Endo Y, Asou HK, Yamamoto T,
Tumes DJ, Tokuyama H, Yokote K and Nakayama T: Fatty acid metabolic
reprogramming via mTOR-mediated inductions of PPARү directs early
activation of T cells. Nat Commun. 7:136832016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Seo YS, Kim JH, Jo NY, Choi KM, Baik SH,
Park JJ, Kim JS, Byun KS, Bak YT, Lee CH, et al: PPAR agonists
treatment is effective in a nonalcoholic fatty liver disease animal
model by modulating fatty-acid metabolic enzymes. J Gastroenterol
Hepatol. 23:102–109. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Small DM, Morais C, Coombes JS, Bennett
NC, Johnson DW and Gobe GC: Oxidative stress-induced alterations in
PPAR-ү and associated mitochondrial destabilization contribute to
kidney cell apoptosis. Am J Physiol Renal Physiol. 307:F814–F822.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vallee A and Lecarpentier Y: Crosstalk
between peroxisome proliferator-activated receptor gamma and the
canonical WNT/β-Catenin pathway in chronic inflammation and
oxidative stress during carcinogenesis. Front Immunol. 9:7452018.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Koundouros N and Poulogiannis G:
Reprogramming of fatty acid metabolism in cancer. Br J Cancer.
122:4–22. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Carracedo A, Cantley LC and Pandolfi PP:
Cancer metabolism: fatty acid oxidation in the limelight. Nat Rev
Cancer. 13:227–232. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ma APY, Yeung CLS, Tey SK, Mao X, Wong
SWK, Ng TH, Ko FCF, Kwong EML, Tang AHN, Ng IO, et al: Suppression
of ACADM-Mediated fatty acid oxidation promotes hepatocellular
carcinoma via aberrant CAV1/SREBP1 Signaling. Cancer Res.
81:3679–3692. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang C, Shao L, Pan C, Ye J, Ding Z, Wu J,
Du Q, Ren Y and Zhu C: Elevated level of mitochondrial reactive
oxygen species via fatty acid beta-oxidation in cancer stem cells
promotes cancer metastasis by inducing epithelial-mesenchymal
transition. Stem Cell Res Ther. 10:1752019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Amoedo ND, Sarlak S, Obre E, Esteves P,
Begueret H, Kieffer Y, Rousseau B, Dupis A, Izotte J, Bellance N,
et al: Targeting the mitochondrial trifunctional protein restrains
tumor growth in oxidative lung carcinomas. J Clin Invest.
131:e1330812021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li XX, Wang ZJ, Zheng Y, Guan YF, Yang PB,
Chen X, Peng C, He JP, Ai YL, Wu SF, et al: Nuclear Receptor Nur77
facilitates melanoma cell survival under metabolic stress by
protecting fatty acid oxidation. Mol Cell. 69:480–492. e72018.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hsieh CH, Cheung CHY, Liu YL, Hou CL, Hsu
CL, Huang CT, Yang TS, Chen SF, Chen CN, Hsu WM, et al:
Quantitative Proteomics of Th-MYCN transgenic mice reveals aurora
kinase inhibitor altered metabolic pathways and enhanced ACADM To
suppress neuroblastoma progression. J Proteome Res. 18:3850–3866.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pacary E, Tixier E, Coulet F, Roussel S,
Petit E and Bernaudin M: Crosstalk between HIF-1 and ROCK pathways
in neuronal differentiation of mesenchymal stem cells, neurospheres
and in PC12 neurite outgrowth. Mol Cell Neurosci. 35:409–423. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Befani C, Mylonis I, Gkotinakou IM,
Georgoulias P, Hu CJ, Simos G and Liakos P: Cobalt stimulates
HIF-1-dependent but inhibits HIF-2-dependent gene expression in
liver cancer cells. Int J Biochem Cell Biol. 45:2359–2368. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhigalova N, Artemov A, Mazur A and
Prokhortchouk E: Transcriptome sequencing revealed differences in
the response of renal cancer cells to hypoxia and CoCl2 treatment.
F1000Res. 4:15182015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhao Y, Lützen U, Gohlke P, Jiang P,
Herdegen T and Culman J: Neuroprotective and antioxidative effects
of pioglitazone in brain tissue adjacent to the ischemic core are
mediated by PI3K/Akt and Nrf2/ARE pathways. J Mol Med (Berl).
99:1073–1083. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jiao XX, Lin SY, Lian SX, Qiu YR, Li ZH,
Chen ZH, Lu WQ, Zhang Y, Deng L, Jiang Y and Hu GH: Inhibition of
the breast cancer by PPARγ agonist pioglitazone through JAK2/STAT3
pathway. Neoplasma. 67:834–842. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tsubaki M, Takeda T, Tomonari Y, Kawashima
K, Itoh T, Imano M, Satou T and Nishida S: Pioglitazone inhibits
cancer cell growth through STAT3 inhibition and enhanced AIF
expression via a PPARγ-independent pathway. J Cell Physiol.
233:3638–3647. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Munoz-Sanchez J and Chanez-Cardenas ME:
The use of cobalt chloride as a chemical hypoxia model. J Appl
Toxicol. 39:556–570. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ran Y, Hu C, Wan J, Kang Q, Zhou R, Liu P,
Ma D, Wang J and Tang L: Integrated investigation and experimental
validation of PPARG as an oncogenic driver: Implications for
prognostic assessment and therapeutic targeting in hepatocellular
carcinoma. Front Pharmacol. 14:12983412023. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hsiao PJ, Chiou HC, Jiang HJ, Lee MY,
Hsieh TJ and Kuo KK: Pioglitazone enhances cytosolic lipolysis,
β-oxidation and autophagy to ameliorate hepatic steatosis. Sci Rep.
7:90302017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Petrova V, Annicchiarico-Petruzzelli M,
Melino G and Amelio I: The hypoxic tumour microenvironment.
Oncogenesis. 7:102018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Simonsen LO, Harbak H and Bennekou P:
Cobalt metabolism and toxicology-A brief update. Sci Total Environ.
432:210–215. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Horev-Azaria L, Kirkpatrick CJ, Korenstein
R, Marche PN, Maimon O, Ponti J, Romano R, Rossi F, Golla-Schindler
U, Sommer D, et al: Predictive toxicology of cobalt nanoparticles
and ions: Comparative in vitro study of different cellular models
using methods of knowledge discovery from data. Toxicol Sci.
122:489–501. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Choi HJ, Jhe YL, Kim J, Lim JY, Lee JE,
Shin MK and Cheong JH: FoxM1-dependent and fatty acid
oxidation-mediated ROS modulation is a cell-intrinsic drug
resistance mechanism in cancer stem-like cells. Redox Biol.
36:1015892020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sprecher DL, Massien C, Pearce G, Billin
AN, Perlstein I, Willson TM, Hassall DG, Ancellin N, Patterson SD,
Lobe DC and Johnson TG: Triglyceride: High-Density Lipoprotein
cholesterol effects in healthy subjects administered a peroxisome
proliferator activated receptor δ agonist. Arterioscler Thromb Vasc
Biol. 27:359–365. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Froment P, Gizard F, Defever D, Staels B,
Dupont J and Monget P: Peroxisome proliferator-activated receptors
in reproductive tissues: From gametogenesis to parturition. J
Endocrinol. 189:199–209. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wagner N and Wagner KD: Peroxisome
proliferator-activated receptors and the hallmarks of cancer.
Cells. 11:24322022. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kuemmerle NB, Rysman E, Lombardo PS,
Flanagan AJ, Lipe BC, Wells WA, Pettus JR, Froehlich HM, Memoli VA,
Morganelli PM, et al: Lipoprotein lipase links dietary fat to solid
tumor cell proliferation. Mol Cancer Ther. 10:427–436. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pepino MY, Kuda O, Samovski D and Abumrad
NA: Structure-Function of CD36 and importance of fatty acid signal
transduction in fat metabolism. Annu Rev Nutr. 34:281–303. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hale JS, Otvos B, Sinyuk M, Alvarado AG,
Hitomi M, Stoltz K, Wu Q, Flavahan W, Levison B, Johansen ML, et
al: Cancer stem cell-specific scavenger receptor CD36 drives
glioblastoma progression. Stem Cells. 32:1746–1758. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang Y, Gu H, Zhang K, Guo Z, Wang X, Wei
Q, Weng L, Han X, Lv Y, Cao M, et al: Exosomal ACADM sensitizes
gemcitabine-resistance through modulating fatty acid metabolism and
ferroptosis in pancreatic cancer. BMC Cancer. 23:7892023.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen D, Feng X, Lv Z, Xu X, Lu Y, Wu W, Wu
H, Liu H, Cao L, Ye S, et al: ACADS acts as a potential methylation
biomarker associated with the proliferation and metastasis of
hepatocellular carcinomas. Aging (Albany NY). 11:8825–8844. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xu R, Luo X, Ye X, Li H, Liu H, Du Q and
Zhai Q: SIRT1/PGC-1α/PPAR-ү correlate with hypoxia-induced
chemoresistance in non-small cell lung cancer. Front Oncol.
11:6827622021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Abe K, Ikeda S, Nara M, Kitadate A, Tagawa
H and Takahashi N: Hypoxia-induced oxidative stress promotes
therapy resistance via upregulation of heme oxygenase-1 in multiple
myeloma. Cancer Med. 12:9709–9722. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lane SL, Dodson RB, Doyle AS, Park H,
Rathi H, Matarrazo CJ, Moore LG, Lorca RA, Wolfson GH and Julian
CG: Pharmacological activation of peroxisome proliferator-activated
receptor ү (PPAR-ү) protects against hypoxia-associated fetal
growth restriction. FASEB J. 33:8999–9007. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kilter H, Werner M, Roggia C, Reil JC,
Schafers HJ, Kintscher U and Bohm M: The PPAR-gamma agonist
rosiglitazone facilitates Akt rephosphorylation and inhibits
apoptosis in cardiomyocytes during hypoxia/reoxygenation. Diabetes
Obes Metab. 11:1060–1067. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Feng J, Dai W, Mao Y, Wu L, Li J, Chen K,
Yu Q, Kong R, Li S, Zhang J, et al: Simvastatin re-sensitizes
hepatocellular carcinoma cells to sorafenib by inhibiting
HIF-1α/PPAR-ү/PKM2-mediated glycolysis. J Exp Clin Cancer Res.
39:242020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liu T, Sun L, Zhang Y, Wang Y and Zheng J:
Imbalanced GSH/ROS and sequential cell death. J Biochem Mol
Toxicol. 36:e229422021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Aldini G, Altomare A, Baron G, Vistoli G,
Carini M, Borsani L and Sergio F: N-Acetylcysteine as an
antioxidant and disulphide breaking agent: The reasons why. Free
Radic Res. 52:751–762. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Han EJ, Im CN, Park SH, Moon EY and Hong
SH: Combined treatment with peroxisome proliferator-activated
receptor (PPAR) γ ligands and gamma radiation induces apoptosis by
PPARγ-independent up-regulation of reactive oxygen species-induced
deoxyribonucleic acid damage signals in non-small cell lung cancer
cells. Int J Radiat Oncol Biol Phys. 85:e239–248. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chen K, Li D, Zhang X, Hermonat PL and
Mehta JL: Anoxia-reoxygenation stimulates collagen type-I and MMP-1
expression in cardiac fibroblasts: Modulation by the PPAR-gamma
ligand pioglitazone. J Cardiovasc Pharmacol. 44:6822004. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Cadenas S: Mitochondrial uncoupling, ROS
generation and cardioprotection. Biochim Biophys Acta Bioenerg.
1859:940–950. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Fuhrmann DC and Brune B: Mitochondrial
composition and function under the control of hypoxia. Redox Biol.
12:208–215. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Sawayama H, Ishimoto T, Watanabe M,
Yoshida N, Sugihara H, Kurashige J, Hirashima K, Iwatsuki M, Baba
Y, Oki E, et al: Small molecule agonists of PPAR-ү exert
therapeutic effects in esophageal cancer. Cancer Res. 74:575–585.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Jin JQ, Han JS, Ha J, Baek HS and Lim DJ:
Lobeglitazone, A peroxisome proliferator-activated receptor-gamma
agonist, inhibits papillary thyroid cancer cell migration and
invasion by suppressing p38 MAPK signaling pathway. Endocrinol
Metab (Seoul). 36:1095–1110. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Jiao HL and Zhao BL: cytotoxic effect of
peroxisome proliferator fenofibrate on human HepG2 hepatoma cell
line and relevant mechanisms. Toxicol Appl Pharmacol. 185:172–179.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Gao J, Liu Q, Xu Y, Gong X, Zhang R, Zhou
C, Su Z, Jin J, Shi H, Shi J and Hou Y: PPARα induces cell
apoptosis by destructing Bcl2. Oncotarget. 6:44635–44642. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Chong SJ, Low IC and Pervaiz S:
Mitochondrial ROS and involvement of Bcl-2 as a mitochondrial ROS
regulator. Mitochondrion. 19(Pt A): 39–48. 2014. View Article : Google Scholar : PubMed/NCBI
|
